atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration Psychedelics
Posted:
atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced a strategic investment in Beckley Psytech Limited (“Beckley Psytech”), a private clinical-stage biotechnology company dedicated to transforming short-duration psychedelics into effective and rapid-acting medicines for neuropsychiatric conditions.
According to the company, the design of the camera was developed to meet the needs of general healthcare providers, including primary care, optometry, retail health clinics and home health settings, and ensure accessibility and practicality in these environments.
Read more…
The NHS is to be allowed to hire physician associates (PA) from Ghana, Zimbabwe and Bangladesh, despite concerns over the quality of their training.
Doctors have been in revolt over the plan to increase the number of PAs and AAs…
Attendees
Sponsors and Exhibitors
AI Training for Doctors Workshops
Contact us